Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Form 144 filed for STOK insider sale. The notice reports a proposed sale of 10,844 common shares with an aggregate market value of $214,277.44 to be executed through Morgan Stanley Smith Barney on NASDAQ on 09/02/2025. The filing identifies the shares as acquired via Restricted Stock Units (03/15/2025), Performance Stock Units (12/31/2024), and the Employee Stock Purchase Plan (06/30/2020), with respective amounts of 6,876, 1,483, and 2,485 shares.
The filing also lists recent dispositions by the same person, including sales on 08/18/2025 (2,805 shares), 08/01/2025 (4,504 shares), 07/01/2025 (4,503 shares), and 06/03/2025 (6,471 shares), several executed under a 10b5-1 plan. The filer affirms no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.
Form 144 notice for Stoke Therapeutics (STOK): An insider proposes to sell 61,885 common shares through Morgan Stanley Smith Barney with an approximate aggregate market value of $1,223,466.45. The filing reports 54,797,418 shares outstanding and an approximate sale date of 08/29/2025 on NASDAQ. Acquisition history shows 27,000 shares from exercised options on 05/25/2022 (paid in cash), 15,421 RSUs on 12/01/2024, and 19,464 PSUs on 12/03/2024. The filing also discloses a prior sale by Edward M. Kaye of 12,126 shares on 08/18/2025 for $221,153.99. Several filer identification fields in the header appear blank in the provided content.
Insider proposed sale and recent activity disclosed. This Form 144 notifies the proposed sale of 22,117 common shares of the issuer via Morgan Stanley Smith Barney, with an aggregate market value of $437,253.09 and an approximate sale date of 08/29/2025 on NASDAQ. The filing shows acquisition details: 10,000 shares acquired on 08/29/2025 by exercise of stock options (paid in cash) and 12,117 shares from restricted stock units acquired on 12/01/2024. The filer previously sold 1,683 shares on 08/18/2025 for $30,694.55 and 13,712 shares on 08/13/2025 for $205,680.00. The notice includes the required attestation regarding material nonpublic information.
Skorpios Trust, Montrago Trustees Ltd, Ezbon International Ltd and Blue Horizon Enterprise Ltd filed Amendment No. 6 to their Schedule 13D for Stoke Therapeutics (STOK). The amendment reports that on August 22, 2025 Blue Horizon sold 1,000,000 shares of common stock in an open-market transaction at $18.50 per share. The filing states that, following that sale, the Reporting Persons ceased to be beneficial owners of more than 5.0% of the outstanding shares, based on 54,797,418 shares outstanding. The amendment incorporates updated cover page figures showing individual shared voting and dispositive power and adds a joint filing agreement as an exhibit.
Insider sale to cover tax withholding on vested RSUs. Dr. Barry Ticho, Chief Medical Officer of Stoke Therapeutics (STOK), disposed of 2,805 shares of common stock in an issuer-mandated sale to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units. The reported weighted-average sale price was $18.238 per share, with individual sale prices ranging from $18.00 to $18.50 per share. After the reported disposition, Dr. Ticho beneficially owns 23,970 shares directly.
This Form 4 reports a routine, non-discretionary sale related to compensation tax withholding rather than an open-market decision to divest additional holdings.
Stoke Therapeutics director Edward M. Kaye sold shares to satisfy tax withholding tied to restricted stock unit vesting. The Form 4 reports an issuer-mandated sale of 12,126 shares of common stock on 08/18/2025 at a weighted average price of $18.238 per share, with individual sale prices ranging from $18.00 to $18.50. After the sale, Dr. Kaye beneficially owned 153,470 shares as a direct owner. The filing indicates the transaction was to cover tax withholding on settled restricted stock units and was signed by an attorney-in-fact on 08/20/2025.
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a transaction on 08/18/2025 selling 1,683 shares of the company's common stock. The filing states this was an issuer-mandated sale to satisfy tax withholding liabilities arising from the vesting and settlement of restricted stock units. The weighted-average proceeds reported were $18.238 per share (sales occurred at prices ranging from $18.00 to $18.50). After the sale, Mr. Allan beneficially owned 23,948 shares. The form is a routine Section 16 disclosure showing an internal tax-related disposition rather than a voluntary market-timed sale.
Stoke Therapeutics insider filing: Chief Medical Officer Barry Ticho reported equity awards and acquisitions dated 08/14/2025. The filing shows a direct acquisition of 10,000 shares of common stock at $0, leaving the reporting person with 26,775 shares beneficially owned after the transaction. The filing also reports grants of performance stock units (PSUs) that each convert to one share: an award of 20,000 PSUs granted as restricted stock units upon certification and an award of 10,000 PSUs reported under a separate transaction code. The PSU awards vest in two equal installments, with half vesting on August 14, 2025 and the remainder on August 14, 2026, subject to continued service. All reported derivative holdings and the acquired common shares are shown as direct beneficial ownership.
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported equity awards and vesting terms. The Form 4 shows transactions dated 08/14/2025 with the filing signed on 08/18/2025. Non-derivative activity records an acquisition of 6,000 shares of common stock at $0, bringing Mr. Allan's direct beneficial ownership to 25,631 shares. Derivative activity shows grants of 12,000 performance stock units (PSUs) and an additional 6,000 PSUs under a modification code; each unit converts to one share of common stock on vesting. The award vests in two equal tranches: half on August 14, 2025 and half on August 14, 2026, subject to continued service and certification of performance criteria.
Edward M. Kaye, M.D., a director of Stoke Therapeutics, Inc. (STOK), reported equity awards and stock units on 08/14/2025. The filing shows an acquisition of 26,250 shares of common stock and that Dr. Kaye beneficially owned 165,596 shares after the transaction. He was also granted performance stock units convertible into 52,500 shares and an additional 26,250 performance stock units, each with an exercise/conversion price of $0. The performance units vest in two equal installments: one on August 14, 2025 and the remainder on August 14, 2026, subject to continued service and certification of performance conditions. The form was signed by an attorney-in-fact on 08/18/2025.